Urbanus Rolf T, Siegerink Bob, Roest Mark, Rosendaal Frits R, de Groot Philip G, Algra Ale
Department of Clinical Chemistry and Haematology, University Medical Centre Utrecht, Utrecht, Netherlands.
Lancet Neurol. 2009 Nov;8(11):998-1005. doi: 10.1016/S1474-4422(09)70239-X. Epub 2009 Sep 25.
Arterial thrombosis is a major clinical manifestation of the antiphospholipid syndrome, which is an autoimmune disease found mostly in young women. Although the presence of circulating antiphospholipid antibodies in individuals who have a thrombotic event is a prerequisite for the diagnosis of the antiphospholipid syndrome, the risk of arterial thrombosis associated with antiphospholipid antibodies in the general population is unclear.
In RATIO (Risk of Arterial Thrombosis In relation to Oral contraceptives), a large multicentre population-based case-control study, we enrolled women aged under 50 years who were admitted to hospital at 16 centres with first ischaemic stroke or myocardial infarction between January, 1990, and October, 1995. An additional 59 women who presented with ischaemic stroke at the University Medical Centre Utrecht between 1996 and 2001 were also enrolled. Information on cardiovascular risk factors (such as oral contraceptive use, smoking, and hypertension) were assessed with a standard questionnaire. During the second phase (1998-2002), blood samples were taken to measure antiphospholipid antibody profiles (lupus anticoagulant, anticardiolipin IgG, anti-beta(2)-glycoprotein I IgG, and antiprothrombin IgG) and to determine genetic prothrombotic risk factors (factor V G1691A variant, prothrombin G20210A variant, and factor XIII 204Phe allele).
175 patients with ischaemic stroke, 203 patients with myocardial infarction, and 628 healthy controls were included. Patients were frequency matched with controls for age, residence area, and index year. Lupus anticoagulant was found in 30 (17%) patients with ischaemic stroke, six (3%) patients with myocardial infarction, and four (0.7%) in the control group. The odds ratio for myocardial infarction was 5.3 (95% CI 1.4-20.8), which increased to 21.6 (1.9-242.0) in women who used oral contraceptives and 33.7 (6.0-189.0) in those who smoked. The odds ratio for ischaemic stroke was 43.1 (12.2-152.0), which increased to 201.0 (22.1-1828.0) in women who used oral contraceptives and 87.0 (14.5-523.0) in those who smoked. In women who had anti-beta(2)-glycoprotein I antibodies, the risk of ischaemic stroke was 2.3 (1.4-3.7), but the risk of myocardial infarction was not increased (0.9, 0.5-1.6). Neither anticardiolipin nor antiprothrombin antibodies affected the risk of myocardial infarction or ischaemic stroke.
Our results suggest that lupus anticoagulant is a major risk factor for arterial thrombotic events in young women, and the presence of other cardiovascular risk factors increases the risk even further.
Netherlands Heart Foundation and Leducq Foundation.
动脉血栓形成是抗磷脂综合征的主要临床表现,抗磷脂综合征是一种主要见于年轻女性的自身免疫性疾病。虽然在发生血栓事件的个体中存在循环抗磷脂抗体是抗磷脂综合征诊断的先决条件,但普通人群中与抗磷脂抗体相关的动脉血栓形成风险尚不清楚。
在RATIO(口服避孕药与动脉血栓形成风险研究)中,一项基于人群的大型多中心病例对照研究,我们纳入了1990年1月至1995年10月期间在16个中心因首次缺血性中风或心肌梗死入院的50岁以下女性。另外还纳入了1996年至2001年期间在乌得勒支大学医学中心出现缺血性中风的59名女性。通过标准问卷评估心血管危险因素(如口服避孕药使用情况、吸烟和高血压)信息情况。在第二阶段(1998 - 2002年),采集血样以检测抗磷脂抗体谱(狼疮抗凝物、抗心磷脂IgG、抗β2糖蛋白I IgG和抗凝血酶原IgG)并确定遗传性血栓形成危险因素(因子V G1691A变异体、凝血酶原G20210A变异体和因子XIII 204Phe等位基因)。
纳入了175例缺血性中风患者、203例心肌梗死患者和628名健康对照者。患者在年龄、居住地区和索引年份方面与对照者进行频率匹配。在17%的缺血性中风患者、3%的心肌梗死患者和0.7%的对照组中发现狼疮抗凝物。心肌梗死的比值比为5.3(95%可信区间1.4 - 20.8),在使用口服避孕药的女性中增至21.6(1.9 - 242.0),在吸烟女性中增至33.7(6.0 - 189.0)。缺血性中风的比值比为43.1(12.2 - 152.0),在使用口服避孕药的女性中增至201.0(22.1 - 1828.0),在吸烟女性中增至87.0(14.5 - 523.0)。在具有抗β2糖蛋白I抗体的女性中,缺血性中风风险为2.3(1.4 - 3.7),但心肌梗死风险未增加(0.9,0.5 - 1.6)。抗心磷脂抗体和抗凝血酶原抗体均未影响心肌梗死或缺血性中风风险。
我们的结果表明,狼疮抗凝物是年轻女性动脉血栓形成事件的主要危险因素,其他心血管危险因素的存在会进一步增加风险。
荷兰心脏基金会和勒杜克基金会。